Citizens reiterated its buy rating and $80 price target for CRISPR Therapeutics on Monday, citing progress in the company’s gene therapy pipeline and regulatory developments.
The Swiss biotech’s shares were trading at about $57.72, roughly 39% below the analysts’ target. Citizens’ valuation is based on a discounted cash flow model. H.C. Wainwright also maintained a buy rating and $80 target.
CRISPR presented data at the European Society of Cardiology Congress on CTX310, an in vivo gene editor targeting ANGPTL3. The therapy demonstrated a durable reduction in ANGPTL3 expression and key cardiovascular biomarkers, supporting its advancement into Phase 1b clinical trials for severe hypertriglyceridemia. Initial results suggest efficacy comparable to monthly antisense oligonucleotide therapies or quarterly siRNA treatments, with the added benefit of single-dose administration.
Separately, the FDA expanded the label for CASGEVY to include patients aged two years and older with sickle cell disease and transfusion-dependent beta-thalassemia. CRISPR’s partner Vertex Pharmaceuticals has submitted regulatory applications for CASGEVY in children aged 5 to 11 with the same conditions across multiple jurisdictions.
Analysts noted that a potential label expansion for CASGEVY could increase the addressable market by 10% to 15%. Wall Street maintains a consensus buy rating on the stock, with 12 analysts recently revising earnings estimates upward. Citizens expects major data releases in the second half of 2026.
